In this episode, Why Location Matters: Country and Site Placement Strategy, we explore why geography is more than a backdrop—it is a strategic lever in early phase oncology trials. From patient access and regulatory timelines to invest...

Rare diseases are often misunderstood—and Primary Sclerosing Cholangitis (PSC) is no exception.This Rare Disease Day, join Fortrea and patient advocate leaders to explore why early patient engagement, smarter trial design, and global col...

In this episode, we talk through what sponsors really need to think about when navigating regulatory pathways for cell and gene therapies. We cover everything from early conversations with regulators and managing CMC risk, to using accelerated ...

In this episode, Fortrea experts discuss how external control arms can enable efficient and ethical cell and gene therapy trials, particularly in rare diseases where traditional control arms are challenging. The conversation highlights study de...

In this episode we focus on one of the most dynamic regions in the CGT space: China. Why is this important? China has roughly become a major hub for cell and gene therapy research, driven by regulatory innovation, technological progress, and si...

In this episode of Accelerating Oncology – Inside the EPON Network, host Maria Garcia discusses why partnerships matter in early phase oncology. We’ll also find out what makes an EPON site different and talk about partnership design prin...

Early Phase Oncology trials have evolved from simple safety checks to the most scientifically demanding stage of cancer drug development. In this episode of Accelerating Oncology – Inside the EPON Network, host Ken Morrison and guest Maria Garc...

Today we explore the unique challenges and opportunities in Phase 1 ophthalmology clinical trials, focusing on gene therapy and inherited retinal diseases. Host: Amber BurgParticipants: David Hoelscher, Senior M...

In today’s episode, we delve into the fascinating world of Phase 1 clinical research at Fortrea’s Leeds Clinical Pharmacology Unit in the UK. We explore the operational challenges and innovative solutions behind a recent, complex ophthalmology ...

In this conversation today, we're going to dive into the evolving landscape of patient recruitment in ophthalmology and explore how Belite Bio and Fortrea are collaborating to overcome protocol complexities, and discuss the unique opportunities...

Join Leone Atkinson, Fortrea’s Executive Medical Director of Neuroscience and Ophthalmology, and Dr. John Huffaker from the Neuropsychiatric Research Center as they discuss the evolving landscape of Alzheimer’s clinical trials. Explore challeng...

In this episode we tackle one of the most critical aspects of these programs: long-term follow-up. Why is it so important? With CAR-T therapies, lentiviral vector-based treatments, and gene editing approaches requiring up to 15 years of follow-...

Expanding cell therapy beyond oncology opens new doors for patients—but it also introduces unique challenges in site identification and startup. From competing studies and resource limitations to regulatory nuances and cross-department collabor...

Host: Louise Kearney, Head of Cell and Gene Therapy, Strategy and Delivery at FortreaParticipant: Frederick DerosierDescription: Cell and gene therapy (CGT) trials are rewriting the rules of early-phase resear...

Host: Louise Kearney, Head of Cell and Gene Therapy, Strategy and Delivery at FortreaParticipants:  Andrea Seres, Senior Director of Strategic, Delivery and Growth in Oncology and Gene Therapy, FortreaMartin Co...

In this episode, host Laura Vidal, VP of Oncology at Fortrea, sits down with Dr. Ron Korn, Founder and Chief Medical Officer of Imaging Endpoints, to explore the evolving role of imaging in precision oncology. The conversation covers the latest...

Host: Louise Kearney, Head of Cell and Gene Therapy, Strategy and Delivery at FortreaParticipants:  Jan Skoumal, Head of Delivery for Oncology, Fortrea  Ludek Sojka, CEO, SCT BioDescription: ...

Host: Louise Kearney, Head of Cell and Gene Therapy, Strategy and Delivery at FortreaParticipant: Isabella Presch, Pediatric Clinical Research and Advanced TherapiesDescription: Today we're diving into one of ...

Host: Louise Kearney, Head of Cell and Gene Therapy, Strategy and Delivery at FortreaParticipant: Darby Thomas, Senior Scientific Director for Cell and Gene Therapies, Fortrea Description: In this first e...

Host: Dr. Mala Puri, Senior Medical Director at Fortrea Participant: Dr. Sanjoy Dutta PhD, Chief Scientific Officer at Breakthrough T1DDescription: This episode brings together Mala Puri, Senior Medical D...

Host: Dr. Mala Puri, Senior Medical Director at Fortrea Participant: Dr. Sanjoy Dutta PhD, Chief Scientific Officer at Breakthrough T1DDescription: This episode brings together Mala Puri, Senior Medical D...

Obesity is a serious, chronic disease with multiple health consequences. Effective treatment should go beyond simply reducing body weight. It must focus on decreasing fat mass, improving body composition including preserving muscle mass and enh...

Host: Dr. Friedrich Mittermayer, Sr. Medical Director for Endocrinology, FortreaParticipant: Dr. Esther Latres PhD, VP of Research at Breakthrough T1DDescription: This episode brings together Dr. Friedrich Mit...

In this episode, we hear from Sarah, a patient living with obesity and a passionate advocate, as she shares her personal experience participating in clinical trials. Sarah reflects on the emotional and practical motivations that drive patients ...

In this episode, we hear from Sarah, a patient living with obesity, as she shares her lifelong journey—from early body image struggles and restrictive dieting to participating in a televised weight-loss transformation. Despite achieving peak fi...